Development and validation of a novel nomogram to avoid unnecessary biopsy in patients with PI-RADS category ≥ 4 lesions and PSA ≤ 20 ng/ml-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development and validation of a novel nomogram to avoid unnecessary biopsy in patients with PI-RADS category ≥ 4 lesions and PSA ≤ 20 ng/ml

Published:2024-08-23 Issue:1 Volume:42 Page:
ISSN:1433-8726
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Zeng Hong,Chen Yuntian,Zhao Jinge,Dai Jindong,Xie Yandong,Wang Minghao,Wang Qian,Xu Nanwei,Chen Junru,Sun Guangxi,Zeng Hao,Shen Pengfei^ORCID

Funder

National Natural Science Foundation of China

1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University

Sichuan Province Science and Technology Support Program

Bethune Foundation, Oncology Basic Research Program

Bethune Foundation, Urological Oncology Special Research Fund

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00345-024-05202-y.pdf

Reference30 articles.

1. Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763

2. Schaeffer EM, Srinivas S, Adra N et al (2022) NCCN guidelines® insights: prostate cancer, version 1.2023. J Natl Compr Canc Netw 20:1288–1298. https://doi.org/10.6004/jnccn.2022.0063

3. Park KJ, Choi SH, Lee JS, Kim JK, Kim MH, Jeong IG (2020) Risk stratification of prostate cancer according to PI-RADS® version 2 categories: meta-analysis for prospective studies. J Urol 204:1141–1149. https://doi.org/10.1097/ju.0000000000001306

4. Oerther B, Engel H, Bamberg F, Sigle A, Gratzke C, Benndorf M (2022) Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis 25:256–263. https://doi.org/10.1038/s41391-021-00417-1

5. Mazzone E, Stabile A, Pellegrino F et al (2021) Positive predictive value of prostate imaging reporting and data system version 2 for the detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 4:697–713. https://doi.org/10.1016/j.euo.2020.12.004

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3